CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted ...
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
TB Alliance has disclosed new ATP-dependent Clp protease ClpP1P2 complex (Mycobacterium tuberculosis) inhibitors reported to be useful for the treatment of tuberculosis.
Protease inhibitors are a promising strategy for enhancing herbivore resistance in plants, which is crucial for addressing the significant yield losses in crops such as tea plants due to insect ...
The role of cytoreductive nephrectomy (CN) in the immune checkpoint inhibitor (ICI) era of metastatic renal cell carcinoma (mRCC): A systematic review and individual patient data (IPD) meta-analysis ...
COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 to be Featured at ICAR2026 On February 19, 2026, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced that initial data from the ongoing Phase ...
Scientists discover novel series of SARS-CoV-2 mpro inhibitors for potential new COVID-19 treatments
New research has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that, according to preclinical testing, effectively inhibits COVID-19 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results